INCYTE CORP (INCY) vs ELI LILLY & Co (LLY)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | INCY | LLY |
|---|---|---|
| Sector | Industrials | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $5.14B | $65.18B |
| Revenue growth (YoY) | ▲ 21.2% | ▲ 44.7% |
| Net income | $1.29B | $20.64B |
| Gross margin | 92.8% | 83.0% |
| Diluted EPS | $6.41 | $22.95 |
| Insider net (6 mo) | +131.3K sh • 15 sells • 0 buys | −31.3K sh • 5 sells • 0 buys |
| Institutional owners | 44 | 51 |
| Institutional value held | $12.27B | $533.23B |
| Next earnings (est.) | Oct 27, 2026 | Around Oct 29, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About INCYTE CORP (INCY)
Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware, with additional operations in Morges, Switzerland; Tokyo, Japan; and Montreal, Canada, focused on the discovery, development, and commercialization of proprietary therapeutics… Read more →
About ELI LILLY & Co (LLY)
Eli Lilly and Company, incorporated in Indiana in 1901 and tracing its roots to a drug manufacturing business founded in 1876, operates as a single-segment human pharmaceutical company focused on discovering, developing, manufacturing, and marketing… Read more →
Source: SEC EDGAR.